PMID- 37265792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230604
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Comparative efficacy and safety of molecular targeted agents combined with 
      transarterial chemoembolization in the treatment of unresectable hepatocellular 
      carcinoma: a network meta-analysis.
PG  - 1179431
LID - 10.3389/fonc.2023.1179431 [doi]
LID - 1179431
AB  - OBJECTIVE: At present, several molecular targeted agents(MTAs) combined with 
      transarterial chemoembolization (TACE) have been employed to treat unresectable 
      hepatocellular carcinoma (HCC). In this meta-analysis, we compared the efficacy 
      and safety of different MTAs combined with TACE to enable effective 
      decision-making for the clinical treatment of unresectable HCC. METHODS: Pubmed, 
      Web of Science, EMBASE, and Cochrane Library were retrieved to evaluate the 
      efficacy and safety of different MTAs combined with TACE in cohort studies and 
      randomized controlled trials. The hazard ratios and 95% confidence intervals 
      (CIs) were calculated to investigate the impact of various therapies on overall 
      survival (OS) and progression-free survival. However, the objective response rate 
      (ORR), disease control rate (DCR), adverse events (AEs), and >/=grade-3 adverse 
      events (>/=G3-AEs) were calculated using odd ratios and 95% CIs. The node-splitting 
      approach was used to test the heterogeneity. The funnel plot was utilized to 
      analyze the publication bias. Additionally, according to the ranking plots, we 
      ranked various treatments. RESULTS: A total of 45 studies involving 10,774 
      patients with 8 treatment strategies were included in our network meta-analysis. 
      Our network meta-analysis showed that apatinib+TACE provided the highest OS 
      (62.2%), ORR (44.7%), and DCR (45.6%), while and lenvatinib+TACE offered the best 
      PFS (78.9%). Besides, there was no statistically significant difference in AEs 
      and >/=G3-AEs among treatment options. CONCLUSION: Apatinib+TACE demonstrated the 
      best OS, ORR, and DCR with no additional AEs and >/=G3-AEs. Therefore, for the 
      treatment scheme of MTAs combined with TACE, apatinib+TACE may be the best option 
      for patients with unresectable HCC. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023388609.
CI  - Copyright (c) 2023 Long, Chen and Liu.
FAU - Long, Jiaye
AU  - Long J
AD  - Department of Interventional Radiology, Inner Mongolia Forestry General Hospital, 
      The Second Clinical Medical School of Inner Mongolia University for The 
      Nationalities, Yakeshi, Inner Mongolia, China.
FAU - Chen, Baoxiang
AU  - Chen B
AD  - Department of Interventional Radiology, Inner Mongolia Forestry General Hospital, 
      The Second Clinical Medical School of Inner Mongolia University for The 
      Nationalities, Yakeshi, Inner Mongolia, China.
FAU - Liu, Zhaohui
AU  - Liu Z
AD  - Department of Urology, Inner Mongolia Forestry General Hospital, The Second 
      Clinical Medical School of Inner Mongolia University for The Nationalities, 
      Yakeshi, Inner Mongolia, China.
LA  - eng
PT  - Systematic Review
DEP - 20230517
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10230082
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - molecular targeted agents
OT  - network meta-analysis
OT  - systematic review
OT  - transarterial chemoembolization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/02 13:16
MHDA- 2023/06/02 13:17
PMCR- 2023/01/01
CRDT- 2023/06/02 10:50
PHST- 2023/03/04 00:00 [received]
PHST- 2023/05/09 00:00 [accepted]
PHST- 2023/06/02 13:17 [medline]
PHST- 2023/06/02 13:16 [pubmed]
PHST- 2023/06/02 10:50 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1179431 [doi]
PST - epublish
SO  - Front Oncol. 2023 May 17;13:1179431. doi: 10.3389/fonc.2023.1179431. eCollection 
      2023.